Curtiss-Wright CW

Reference table

1. What they actually sell — the segments, with real numbers

Curtiss-Wright's product disclosure is the best in this batch — six lines with five years of history. FY25 revenue was $3,498M, +12.1%.

Note: the geographic figures sum to $3,300.9M against total FY25 revenue of $3,498M — a $197M gap the file does not explain. Flagged rather than reconciled.

Three things fall out of this table.

1. Naval Defense plus Power & Process is $1,576.8M — 45.1% of revenue — growing at a combined 15.6%. These are the nuclear-adjacent lines: reactor components and propulsion equipment for submarines and carriers, and control and process equipment for power generation. This is the entire reason the stock is at 44x forward earnings, and it is a real, funded, multi-decade demand cycle rather than a narrative.

2. Five of six lines grew double digits. Only General Industrial, at $412.1M, is flat (+0.4%) and it has actually shrunk 4.3% over two years. That is 11.8% of revenue acting as a drag — significant enough to explain part of the gap between 15%+ segment growth and 12.1% consolidated growth, and a reason consensus models only 8% going forward.

3. 77.2% United States revenue means this is substantially a US government-linked business. That is a source of visibility (multi-year programmes) and of risk (appropriations, continuing resolutions).

Note the segment-definition change. The FY20 and earlier disclosures use a different taxonomy ("Controls," "Flow Control," "Surface Technologies" through FY17, then a six-line defence-oriented split from FY18). Comparisons across the FY17/FY18 boundary are not meaningful and are not attempted here.

2. The margin story — the actual achievement

This is what makes Curtiss-Wright a genuinely good company, and it deserves to be shown properly.

Read the operating margin row: 12.1% to 18.2% in five years — 610 basis points. That is achieved with gross margin essentially flat at 35-37%, so the expansion comes entirely from operating expense discipline: SG&A plus R&D fell from 20.4% of revenue (FY20) to 19.0% (FY25) while revenue grew 46%. Combined with a 10.5% reduction in share count, GAAP diluted earnings per share nearly tripled — $4.80 to $12.87 — on 46% revenue growth.

That is exactly what a well-run industrial compounder looks like, and there is no criticism to make of it.

The quarterly trend confirms it is continuing:

Note something unusual and welcome: the gap between GAAP and adjusted earnings is tiny — $3.46 versus $3.48 in the most recent quarter, roughly 0.6%. Across this batch, GAAP-to-adjusted gaps run from 20% (LPLA) to sign-flipping (MDB). Curtiss-Wright's adjusted numbers are essentially its real numbers, which materially raises the quality of the forward estimates and is worth stating explicitly as a positive.

Trailing twelve months: revenue $3,606.5M, operating income $666.5M (18.5% margin), GAAP diluted EPS $13.66.

3. Balance sheet and cash flow — conservative and well managed

FY25 year-end: cash $371.3M; inventory $615.1M; total current assets $2,018M; property, plant and equipment $580.8M; goodwill $1,692M; intangibles $532.4M; total assets $5,221M; short-term debt $200.0M; long-term debt $936.4M; total debt $1,315M; total liabilities $2,688M; equity $2,534M.

• Net debt: $1,315M − $371.3M = $943.5M, giving an enterprise value of $28,564M (the vendor reports $28,425M — a small and immaterial difference, unusually).
• Leverage: $943.5M against trailing EBITDA of $818.0M = 1.15x. Conservative. Interest coverage is 15.5x. No balance-sheet concern whatsoever.
• Goodwill plus intangibles of $2,224M against $2,534M of equity leaves tangible book value at $430.4M, or $11.67 per share, against a $747.67 price. This is an acquisitive business — $287.5M (FY22), $225.5M (FY24), $9.6M (FY25) — and the equity value is entirely the earnings stream, not the assets. Normal for this model; worth knowing.

Three excellent facts here.

1. Free cash flow has compounded from $256.6M to $553.7M in three years — 29% annually — and converts 114% of net income. Capital expenditure is 2.6% of revenue.

2. Stock-based compensation is $21.5M, just 0.6% of revenue. This is the lowest in the batch by an enormous margin (MongoDB is at 22.3%, Zoom at 15.6%). Curtiss-Wright's earnings are real cash earnings and its share count genuinely falls.

3. Buybacks accelerated sharply to $464.9M in FY25 — 1.7% of today's market capitalisation and 84% of free cash flow. Combined with the $34.7M dividend, total shareholder yield is roughly 1.8%.

The one thing to note against all of this: free cash flow of $553.7M against a market capitalisation of $27.62B is a 2.0% free-cash-flow yield, and against an enterprise value of $28.56B it is 1.9%. Excellent business; expensive claim on it.

4. Valuation — priced in or room?

At $747.67 (market cap $27.62B, EV $28.56B), trailing revenue is $3,606.5M, trailing EBITDA is $818.0M, and trailing GAAP diluted EPS is $13.66.

\*Measured against FY25 adjusted EPS of ~$13.24 (the sum of the four reported quarterly adjusted figures).

Look at the bottom row. FY28E, FY29E and FY30E EPS each carry exactly ONE analyst. FY26E and FY27E carry four. This is the thinnest forward earnings coverage in the batch by a wide margin (MongoDB has 20, Zoom has 16, Reddit has 19-23). Any argument of the form "it's only 32x FY30" rests on a single person's spreadsheet, and this dive will not make that argument. All valuation work below uses FY26E and FY27E, with FY28E used only for the bull case and explicitly caveated.

6a. What today's price assumes (the inversion)

At $747.67 — 43.8x FY27E consensus adjusted EPS, 54.7x trailing GAAP, and 7.9x EV/sales — the price embeds roughly:

• Revenue compounds at ~8% annually from the trailing $3.61B to $4.43B by FY28. (Source: consensus, 6 revenue analysts.) Falsifier: any quarter below +6% year-over-year growth. Recent quarters ran +8.8% to +14.9%, so consensus is modelling deceleration from the current pace — a reasonable assumption after a strong run.
• Operating margin continues expanding past 18.2%, delivering ~13% annual earnings growth on ~8% revenue growth. (Our arithmetic from consensus EPS.) This assumes a SEVENTH consecutive year of margin expansion after 610 basis points already delivered. Falsifier: operating margin below 17% in any quarter.
• The market keeps paying ~40x or more. At an unchanged price the multiple rolls from 49.1x to 38.7x FY28E. For a business consensus models growing revenue 8% a year, that is the assumption doing the most work in the price — and unlike the multiple assumptions elsewhere in this batch, it is not supported by a growth rate that would normally command it.
• Buybacks continue near the $465M FY25 pace, shrinking the share count roughly 1.7% annually and contributing meaningfully to per-share growth. (Cash flow statement.) Falsifier: a large acquisition redirecting capital — the company spent $287.5M and $225.5M on deals in FY22 and FY24.
• THE MOST FRAGILE ASSUMPTION: that a 43.8x multiple is sustainable on an 8% revenue grower. This is not an operating assumption; it is a sentiment assumption. The nuclear and naval demand cycle is real, funded and multi-decade — but demand visibility does not change the arithmetic that 8% revenue growth plus 5 points of margin-and-buyback contribution produces roughly 13% earnings growth, and 13% earnings growth does not historically support a 44x multiple. Falsifier: any broad de-rating in the defence or nuclear complex, or a single quarter where margin expansion stalls.

6b. The return bridge (why the multiple moves)

Expected return ≈ EPS growth + multiple drift + shareholder yield.

Our base case of $650 is built as 38.0x FY27E consensus adjusted EPS of $17.09 = $649. This explicitly assumes multiple COMPRESSION, from 43.8x today to 38.0x — roughly 13%.

The justification, stated plainly: Curtiss-Wright's earnings growth is running at 12-15% and consensus models it decelerating to 9-10% by FY29-30. A business growing earnings at low-teens rates with 8% revenue growth is, by any conventional standard, a 25-32x business. We are assigning 38x — a substantial premium to that — in recognition of the genuine quality: 610 basis points of demonstrated margin expansion, a GAAP-to-adjusted gap of under 1%, stock compensation at 0.6% of revenue, 1.15x leverage, and 45% of revenue in a funded multi-decade nuclear and naval cycle. That premium is deliberate and generous. Even so, 38x on FY27E is 13% below spot.

Decomposing the -13% base case: adjusted EPS grows 12.2% from FY26E to FY27E; the multiple compresses 13%; shareholder yield adds 1.8%. Earnings growth and multiple compression roughly cancel, and the shareholder is left with the dividend and buyback. That is what "fully valued" means arithmetically — the business works and the stock does not.

For the return to be positive from here, the multiple must HOLD at 43.8x. That is the bull case, and it is a sentiment bet rather than a fundamental one.

6c. Variant perception (where we differ, what would surprise)

• We differ from the street on the multiple, and mildly. Consensus targets average $811.50 (+8.5%) with a range of $748 to $870. The LOW target of $748 is today's price to within a dollar. That is a remarkable configuration: not a single covering analyst sees meaningful downside, and the average sees less than 9% of upside. The street is saying, in effect, "correctly valued." We are saying "modestly overvalued." The gap between our $650 and their $811.50 is one multiple turn of disagreement — 38x versus 47x — not a disagreement about the business.
• Where we AGREE with consensus entirely: the operations. Five of six segments growing double digits, six years of margin expansion, five consecutive earnings beats, a 0.6% stock compensation ratio and 114% free-cash-flow conversion. We have no negative view on this company at all, and the dive says so repeatedly.
• Our genuine variant perception is about estimate quality, not about the business. The FY28, FY29 and FY30 EPS estimates each carry ONE analyst. Anyone building a case on "it's only 32x FY30" is extrapolating a single spreadsheet four years forward. We think the market is treating a thin out-year consensus as though it were a robust one, and that is the specific analytical error this dive identifies.
• Positive surprise that would force a repricing: a step-change in Naval Defense or Power & Process — a major programme award or a nuclear order that visibly lifts the 8% revenue trajectory toward the low teens. At 12-13% revenue growth rather than 8%, a 44x multiple becomes defensible and our base case rises toward $800. Watchable at: 2026-08-05 and subsequent segment disclosures.
• Negative surprise: operating margin stalling below 17.5% after six years of expansion, or a large debt-funded acquisition that redirects the buyback. Either would remove the mechanism producing 13% earnings growth on 8% revenue growth, and at 43.8x there is no cushion. Watchable at: 2026-08-05, tomorrow.

Synthos fair values

• Bear ~$510 (-32%). Defence appropriations tighten or a continuing resolution delays programme awards; margin expansion stalls after six years; the market re-rates an 8% grower toward a normal quality-industrial multiple of 30x FY27E adjusted EPS of $17.09 = $513. Note this is 8% above the $472.43 52-week low, i.e. the market visited a comparable level within the last twelve months.
• Base ~$650 (-13%). 38.0x FY27E adjusted EPS of $17.09. A generous quality premium to a low-teens earnings grower, explicitly assuming 13% multiple compression from today's 43.8x.
• Bull ~$870 (+16%). 45.0x FY28E adjusted EPS of $19.30 = $869, matching the street's high target. Requires the current multiple to hold essentially unchanged AND the single-analyst FY28 estimate to prove correct. Both caveats are stated because both matter.

5. Knowledge base — zero claims, and the one hit is a pure collision

A systematic search on CW and Curtiss-Wright returns exactly one result, and it has nothing to do with the company.

michael_levin (2021-11-19, conviction 65, bullish), categorised under photobiomodulation, pulsing and traumatic brain injury:

> "Pulsing 810nm light at 10Hz outperformed 100Hz and CW in TBI models, likely by resonating with the brain's 10Hz alpha rhythm."

Here "CW" means continuous wave — a mode of laser or light emission, contrasted with pulsed emission. This is a developmental-biology claim about light therapy in brain-injury research. It is a textbook ticker collision of exactly the kind that has previously polluted single-name lanes in this system, and it is documented here rather than counted.

We therefore record kb_claim_count: 0 and kb_breadth: 0. This dive is fundamentals and quant-driven only — an accepted, precedented outcome, and never a reason to manufacture conviction. The absence widens the appropriate fair-value band — which is why the range runs $510 to $870, a 1.7x spread — but it does not shift the centre.

It is worth noting the pattern across this batch: short, common ticker symbols (CW, SYM, ZM, MDB) generate collision hits at high rates, and two-letter tickers in particular are almost guaranteed to. The discipline of reading every hit rather than counting it is what separates a 0-claim honest answer from a 1-claim false one.

6. Technicals — extended, untested, and neutral

• Price $747.67 (+3.27% today), -5.7% from the $792.77 52-week high, +58.3% above the $472.43 low.
• Essentially ON the 50-DMA ($744.19) — within 0.5% — and +12.2% above the 200-DMA ($666.33). The 50-DMA sits well above the 200-DMA: a healthy, established uptrend.
• RSI 49.0 — precisely neutral, the most neutral reading in the batch. MACD -6.23, mildly negative, indicating the recent uptrend has paused.
• The number that matters most: maximum drawdown from peak is -5.7%. This stock has never meaningfully corrected in the period covered by this data. Every other name in this batch has a max drawdown between 38% and 83%. Curtiss-Wright has not been tested, which means we have no evidence about how a 44x multiple behaves under pressure in this specific security.
• Relative performance: +52.5% over twelve months against SPY +19.9% — 33 points of outperformance. Three-month +4.8% and six-month +13.9%, so the run has been steady rather than a spike.
• Beta 0.863. Average volume 269,200 shares against a $27.6B market capitalisation — genuinely thin. Position sizing should account for liquidity.

The technical read: a strong, orderly uptrend at a neutral momentum reading, sitting on its 50-DMA. There is no urgency in either direction. The absence of any drawdown history is itself the notable fact — a stock that has only gone up tells you nothing about what it does when the multiple is questioned.

7. Moat & competitive position

Curtiss-Wright's moat is qualification and specification lock-in on long-lived platforms, which is one of the most durable forms of industrial advantage that exists.

The mechanism: components going into naval nuclear propulsion, reactor control systems and flight-critical avionics must be qualified — tested, certified, and written into the programme specification. Once a part is specified into a submarine class or a reactor design, changing supplier requires requalification, which costs money, consumes schedule, and introduces risk into a programme where risk is unacceptable. Incumbency therefore lasts the life of the platform, and naval platforms live for decades.

The evidence is in the margins. Six consecutive years of operating margin expansion — 12.1% to 18.2% — with gross margin flat at 35-37%. A business without pricing power and without incumbency does not expand operating margin through a period of general cost inflation. Interest coverage of 15.5x and a 114% free-cash-flow conversion rate confirm the earnings are real.

Three constraints, stated honestly:

1. Growth is set by programme schedules and appropriations, not by the company. 77.2% United States revenue and heavy government exposure mean the customer decides the growth rate. This is precisely why an excellent moat produces only 8% revenue growth — and why paying 44x for it is the error.

2. General Industrial, at $412.1M and -4.3% over two years, is outside the moat and is a genuine drag on 11.8% of revenue.

3. The moat was partly acquired. Goodwill and intangibles of $2,224M exceed 87% of equity, built through $522M of acquisitions across FY22 and FY24. Roll-ups require continued integration competence, and the file gives no visibility into acquired-business performance.

Verdict on the moat: wide, durable, specification-locked — and structurally incapable of producing more than high-single-digit revenue growth. That combination is exactly what makes this a superb business and a poor stock at 44x.

8. Data integrity — what we rejected and why

Vendor data corruption checking is standard for these dives. CW is the cleanest file in this batch, which is worth saying.

• REJECTED: the consensus EBIT and EBITDA series. The est block reports FY22E EBIT of $138.1M against reported FY22 operating income of $1,167M — off by a factor of 8.5. The FY25E row shows EBIT of $604.6M against reported $638.0M, closer but still inconsistent, and the FY25E EBITDA of $742.6M against reported $788.0M shows the same drift. The series is not internally consistent across years and is excluded. Only revenue, net income and EPS from est are used.
• FLAGGED AS THE PRIMARY ESTIMATE-QUALITY ISSUE: numAnalystsEps = 1 for FY28E, FY29E and FY30E. Four contributors for FY26E and FY27E; one for each of the three years beyond. This is the thinnest forward coverage in the batch and it directly caps how far the valuation horizon can honestly be extended. All base and bear cases use FY27E; FY28E is used only for the bull case with the caveat stated inline.
• FLAGGED: the geographic revenue disclosure does not sum to total revenue. FY25 shows United States $2,548.2M plus Other Foreign Countries $752.6M = $3,300.9M against total revenue of $3,498M — a $197M gap (5.6%) the file does not explain. The same pattern appears in prior years. Flagged; the segment percentages in this dive are computed against the disclosed total and labelled accordingly.
• FLAGGED, minor: an insider-award price that does not match the market. Five officer share awards dated 2026-07-06 are recorded at $634.88 while the stock traded near $740 in that period. This is almost certainly a plan-formula or grant-date-average price rather than a market transaction, but the file does not say. Noted so it is not misread as an insider purchase at a discount.
• NOTE: insider activity is modest and one-directional. CEO Lynn Bamford sold 2,500 shares at $758.20 (2026-06-12) against a 45,600-share position; EVP John Watts sold 200 at $770.56; Senior VP Gary Ogilby sold 399 at $721.95. All sales, no open-market purchases, but the volumes are small relative to holdings and the prices are near the highs. Mildly negative as a signal; not decisive.
• NOTE, and it is a positive: the GAAP-to-adjusted gap is under 1%. Q1'26 GAAP diluted EPS of $3.46 against an adjusted $3.48; FY25 GAAP $12.87 against an adjusted sum of ~$13.24. Across this batch, adjusted-earnings gaps run from 20% to sign-flipping. Curtiss-Wright's adjusted numbers are essentially its GAAP numbers, which materially raises the reliability of the forward estimates and is the single best data-quality fact in this dive.
• NOTE: the vendor's enterprise value of $28,425M is close to our computed $28,564M — a 0.5% difference, the smallest discrepancy in this batch. Cash of $371.3M is genuine cash with no short-term investment portfolio to overlook. No correction required, which is itself unusual here.
• GAP: no backlog disclosure. For a long-cycle defence and nuclear supplier, contracted backlog is the single most informative forward indicator and it is absent from this file.
• GAP: no segment operating income. We can see revenue by product line but not profitability, so we cannot tell whether the 610 basis points of margin expansion came from Naval, from Power & Process, or from mix.

9. Verdict, kill-criteria & flip conditions

Watch. Curtiss-Wright is the best-executed business in this batch and this dive has made that case at length: operating margin from 12.1% to 18.2% across six years, earnings per share from $4.80 to $12.87, five of six product lines growing double digits, Naval Defense and Power & Process at 45% of revenue compounding 15.6% on a funded multi-decade nuclear and naval cycle, free cash flow compounding 29% annually to $553.7M at 114% conversion, stock compensation of just 0.6% of revenue, leverage of 1.15x, and a GAAP-to-adjusted gap under 1%. There is no operational criticism to make.

The price is the entire problem. At $747.67 — 54.7x trailing GAAP and 43.8x FY27 consensus adjusted earnings — for a business consensus models growing revenue 8.0% a year, the multiple is doing work the growth rate cannot support. The street's own target is 8.5% above spot with a low target exactly at today's price. The out-year estimates that make the multiple look tolerable each carry one analyst. The stock is +52.5% over twelve months with a maximum drawdown of 5.7% — it has never been tested. There is no knowledge-base support of any kind. And the free-cash-flow yield is 2.0%.

Base fair value $650, thirteen percent below spot. That is not a bearish call on the company; it is an arithmetic statement about what 38x — a generous premium to a low-teens earnings grower — produces on FY27 estimates.

Position protocol:

1. If you own it: hold, do not add. The business is compounding and there is no thesis break. Selling a wide-moat compounder because it is 13% expensive is usually a mistake.

2. If you do not own it: watchlist at $620-660. At $650 the base case becomes neutral and the bear case at $510 is a tolerable -22% rather than -32%. The stock traded at $472 within the last twelve months, so this zone is not hypothetical.

3. Do not chase tomorrow's print. Five consecutive beats mean a beat is the expectation. A sixth beat does not fix 43.8x.

Pre-registered KILL / stay-away criteria (confirming the Watch):

• Operating margin below 17.5% in any quarter — six years of expansion is a long run, and the entire earnings-growth-above-revenue-growth mechanism depends on it continuing.
• Revenue growth below +6% in any quarter, breaking the consensus 8% path at a multiple with no cushion.
• A large debt-funded acquisition that redirects the $465M buyback — the company spent $287.5M and $225.5M on deals in FY22 and FY24, so this is management's demonstrated behaviour.
• Naval Defense or Power & Process growth falling below 10% — these two lines are 45% of revenue and are the entire reason for the premium multiple.
• A defence appropriations disruption or extended continuing resolution affecting programme awards.

Pre-registered FLIP TO STAGE-IN:

• Price at $620-660 with the operating trend intact. This is the primary trigger and it is purely a price trigger, because nothing about the business needs fixing.
• Revenue growth accelerating above 12% for two consecutive quarters, which would break the consensus 8% assumption and make a 44x multiple genuinely defensible — raising the base case toward $800.
• Analyst coverage on the out-years broadening from one contributor to four or more, which would give the longer-horizon multiple a real foundation rather than a single spreadsheet.
• Any backlog disclosure that materially exceeds the implied revenue path.

Where CW fits in the Synthos Framework Portfolio. The defence / nuclear-industrial sleeve, currently at 0% weight with watchlist entry at $620-660 and a 2-3% core target once there. Its portfolio function would be genuine: beta 0.863, a 610-basis-point demonstrated margin expansion, minimal stock compensation and a multi-decade funded demand cycle make it a quality ballast, complementary to the high-beta growth names in this batch. Note the liquidity constraint — 269,200 average daily shares against a $27.6B capitalisation is thin, and position sizing should reflect it. Logged as a tracked Synthos call (Watch) as of 2026-08-04 at $747.67.

Single biggest risk: multiple compression with no cushion beneath it. At 43.8x FY27 consensus adjusted earnings for an 8% revenue grower, with a maximum drawdown of just 5.7% in the entire data history and out-year estimates carried by a single analyst, the equity has no valuation support and no tested behaviour under stress. The most fragile assumption in today's price is that a seventh consecutive year of operating margin expansion arrives — because 8% revenue growth alone produces 8% earnings growth, and it is the margin plus the buyback that turns that into the 13% consensus expects. If the margin stalls at 18.2%, consensus FY27 earnings do not arrive, and a 44x multiple on a missed 8% grower resolves toward the $510 bear case very quickly.

Provenance & disclosures

• Traceability: ZERO knowledge-base claims. A systematic search on CW and Curtiss-Wright returned one result — michael_levin (2021-11-19, conviction 65) on pulsed 810nm light outperforming continuous wave (CW) in traumatic brain injury models. A pure ticker collision, documented rather than counted. kb_claim_count: 0, kb_breadth: 0. This dive is fundamentals and quant-driven only — an accepted, precedented outcome. The absence widens the fair-value band without shifting its centre.
• Data as-of: fundamentals 2026-03-31 (Q1'26, filed 2026-05-07) · estimates 2026-08-04 · prices 2026-08-04 ($747.67, +3.27%; 50-DMA $744.19, 200-DMA $666.33, RSI 49.0, beta 0.863) · KB search 2026-08-04. Sole data source: scripts/deepdive/vti_data/CW_data.json.
• Rejected data: the consensus EBIT and EBITDA series (FY22E EBIT of $138.1M against reported operating income of $1,167M, off 8.5x; internally inconsistent across years).
• Flagged data: numAnalystsEps = 1 for FY28E, FY29E and FY30E — the thinnest forward coverage in this batch, and the reason all base and bear valuation work stops at FY27E; geographic revenue disclosure that does not sum to total revenue (a $197M / 5.6% gap in FY25, recurring in prior years); insider award transactions dated 2026-07-06 recorded at $634.88 against a market price near $740, almost certainly a plan-formula price rather than a market transaction.
• Positive data note: the GAAP-to-adjusted earnings gap is under 1% (Q1'26: $3.46 GAAP versus $3.48 adjusted), the smallest in this batch by a wide margin, which materially raises confidence in the forward estimates. The vendor enterprise value of $28,425M is within 0.5% of our computed $28,564M — no correction required, also unusual in this feed.
• Disclosed gaps: no contracted backlog disclosure, which for a long-cycle defence and nuclear supplier is the single most informative absent forward indicator; no segment operating income, so the source of the 610 basis points of margin expansion cannot be attributed; no acquired-business performance detail despite $522M of deals across FY22 and FY24.
• Segment-definition note: the product taxonomy changed at the FY17/FY18 boundary (from Controls / Flow Control / Surface Technologies to the current six-line defence-oriented split). Comparisons across that boundary are not meaningful and are not attempted.
• Fair-value caveat: the $510 / $650 / $870 anchors are scenario multiples applied to consensus adjusted EPS, labelled at each step. The base case explicitly assumes multiple compression from 43.8x to 38.0x, and the 38x itself is stated as a deliberate quality premium to what a low-teens earnings grower would normally command. The bull case relies on the single-analyst FY28E estimate and says so. This is scenario arithmetic, not a discounted-cash-flow model.
• Not investment advice. Independent research, educational and informational only, never personalized. Nothing here is a recommendation to buy or sell any security.
• Version: 2026-08-04-full.